LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it will release top-line data from its Phase IIa trial of SPL026 in Major Depressive Disorder (“MDD”) prior to market-open tomorrow on Wednesday…


Previous articleDiamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin
Next articleGH Research Provides Business Updates and Highlights Key Upcoming Milestones